Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2012. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the Deferred Investment Award Programme.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction notifications rather than financial performance metrics.
Material Changes
No material changes to financial performance or operations are reported in this filing. The document details increases in notional interests in Ordinary Shares for specific individuals following the re-investment of the dividend paid on October 4, 2012.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risks, contingencies, or unusual items. It strictly reports compliance with Disclosure and Transparency Rule 3.1.4R(1)(a) regarding share transactions.
Important Facts for Investors
- Transaction Type: Increases in notional interests in Ordinary Shares via the Deferred Investment Award Programme.
- Transaction Date: Notified on October 10, 2012, following a dividend reinvestment on October 4, 2012.
- Share Price: Transactions occurred at a price of 1460.25 pence per Share.
- Participants: Includes Mr S A Hussain, Mr D S Redfern, Ms C Thomas, Dr P J T Vallance, Ms E Walmsley, Mr C Weber, and Mrs V A Whyte.
- Financial Data: This filing does not contain financial statements or performance data.